Bronchobos syrup 125mg / 5ml, 200ml

Acute and chronic bronchopulmonary diseases, accompanied by a violation of the formation and excretion of mucus, inflammatory diseases of the middle ear and paranasal sinuses; preparation of the patient for bronchoscopy or bronchography.

Inside with liquid.

Capsules. Swallow whole. Adults and children over 12 years old - 2 caps. 3 times a day.

Syrup. Children 2Ц4 years old Ч 2.5Ц5 ml of 2.5% syrup (1/2Ц1 tsp) 4 times a day or 2.5Ц5 ml of 5% syrup (1/2Ц1 tsp). spoon of 5% syrup) 2 times a day, 4-12 years - 10 ml of 2.5% syrup (2 teaspoons) or 5 ml of 5% syrup (1 teaspoon) 3 times a day.

Syrup 2.5% in the form of a transparent slightly viscous liquid from pink to red, with a raspberry scent.

5 ml (1 measuring spoon)

carbocisteine ??125 mg

Excipients: glycerol - 135 mg, ethanol 96% - 125 mg, sodium hydroxide - 30.5 mg, sodium carmellose - 20 mg, citric acid monohydrate - 5 mg, methyl parahydroxybenzoate - 9 mg, sodium saccharinate - 5 mg, propyl parahydroxybenzoate - 1 mg, raspberry flavor - 0.7 mg, azorubin CI14720 (E122) - 0.05 mg, purified water - up to 5 ml.

Hypersensitivity to carbocisteine ??or other components of the drug, gastric ulcer and duodenal ulcer, renal dysfunction, acute glomerulonephritis, cystitis, pregnancy, breastfeeding, children under 2 years of age (for syrup) and up to 12 years (for capsules).

pharmachologic effect

Mucolytic and expectorant drug. Mucolytic and expectorant action is due to the activation of sialic transferase - an enzyme of the goblet cells of the bronchial mucosa. Normalizes the quantitative ratio of acidic and neutral sialomucins of bronchial secretions. Reduces the viscosity of bronchial secretions and discharge from the paranasal sinuses, facilitates the discharge of sputum and mucus, and reduces coughing. Promotes the regeneration of the mucous membrane, normalizes its structure, activates the activity of the ciliated epithelium. Restores the secretion of IgA immunoglobulin (specific protection) and the number of sulfhydryl groups of mucus components (non-specific protection), improves mucociliary clearance.

Pharmacokinetics

Absorption and distribution

Carbocisteine ??is rapidly absorbed after oral administration. Bioavailability is low (less than 10% of the dose taken). Cmax in blood serum and in the mucous membrane of the respiratory tract is achieved 2-3 hours after ingestion of the drug and remains in the mucous membrane for 8 hours.

Metabolism and excretion

Metabolized in the liver (has a 'first pass' effect through the liver). It is excreted mainly by the kidneys, partly unchanged, partly in the form of metabolites. T1 / 2 - about 2 hours

Side effect

From the digestive system: sometimes - nausea, vomiting, diarrhea, epigastric pain, gastrointestinal bleeding.

Allergic reactions: in isolated cases - itching, urticaria, exanthema, angioedema.

Others: dizziness, weakness, malaise.

In patients with bronchial asthma and in elderly patients, airway obstruction may occur.

Application during pregnancy and lactation

The drug in the form of a syrup is contraindicated for use during pregnancy and lactation (breastfeeding).

The drug in the form of capsules is prescribed in the II and III trimesters of pregnancy only if the intended benefit to the mother outweighs the potential risk to the fetus.

If it is necessary to prescribe the drug during lactation, the issue of stopping breastfeeding should be resolved.

Application for violations of liver function

Contraindication: liver disease (for taking syrup);

Application for impaired renal function

Contraindication: chronic glomerulonephritis in the acute phase.

Application in children

Contraindications: children under 3 years of age (for taking 2.5% syrup); children under 15 years of age (for taking capsules and syrup 5%).

special instructions

In patients with a history of peptic ulcer disease, the dose of the drug should be reduced. Treatment can be combined with physiotherapy treatments.

The ethanol content in the syrup is 125 mg / 5 ml, i.e. 125 mg ethanol per scoop.

Influence on the ability to drive vehicles and mechanisms

The effect of the drug on the ability to drive vehicles and perform work requiring a high concentration of attention and speed of psychomotor reactions has not been studied.

Overdose

Symptoms: stomach pain, nausea, diarrhea.

Treatment: symptomatic.

Drug interactions

Increases the effectiveness of glucocorticoid (mutually) and antibacterial therapy of infectious and inflammatory diseases of the upper and lower respiratory tract.

Potentiates the bronchodilator effect of theophylline.

The activity of carbocisteine ??is weakened by antitussives and atropine-like drugs.

Due to the ethanol content, BronchobosЃ in the form of a syrup is prescribed with caution:

• with drugs that cause adverse reactions (fever, skin redness, vomiting, tachycardia) when taken simultaneously with alcoholic beverages: disulfiram, cefamandol, cefoperazone, latamoxef (cephalosporin antibiotics), chloramphenicol (a phenicol antibiotic), chlorpropylamide, glibentamide a sulfonylurea derivative), griseofulvin (antifungal drug), nitro-5-imidazoles (metronidazole, ornidazole, secnidazole, tinidazole), ketoconazole, procarbazine (cytostatic);

• with drugs that depress the central nervous system.